Medical Fraternity Appeals For Review of DMO’s Drug Refusal
To the shock of millions of British diabetic patients, the new guidelines issued by the National Institute for Health and Clinical Excellence (Nice) has suggested not to use Lucentis as drug for diabetic macular oedema (DMO).
It’s being believed that the manufacturer, Novartis, had not ascertained the incremental cost-effectiveness for Lucentis, also known as ranibizumab, accurately as compared to the standard laser therapy for DMO.
Confirming the news, Sir Andrew Dillon, Nice’s Chief Executive, said: “The independent appraisal committee was acutely aware visual impairment can have a substantial negative impact on quality of life and activities of daily living in people with DMO, especially since it can affect people’s ability to manage their diabetes”.
With the report making reverberations in the contours of medical fraternity, the charity and eye health experts have appealed the Nice’s think tank and Novartis to make collaborative attempt to resolute the matter, thereby putting patient’s health as top most priority as a large number of people with diabetes would be forced to bear the risk of losing their vision.
In addition, Sarah Rochira, Director of RNIB Cymru, has expressed grave concern about the dire consequences of this step on thousands of diabetic patients and further, called for swift action.
New Zealand News
- Tesla Model Y Performance becomes little bit more expensive to order in China
- Porsche’s recently unveiled Mission R Concept previews electric race cars of future
- Chinese manufacturer GAC’s Aion V e-SUV can charge 0-80% in just 8 minutes
- Oshidori International exits Japanese casino race, citing serious ethical irregularities
- CATL and LG Energy account for nearly 54% of global xEV battery market: SNE Research
- Micro Mobility shows off production version of Microlino 2.0 and 3-wheeled e-scooter
- Chinese electric motorcycle maker Evoke Motorcycles to set up shops in Spain
- TenneT adds more electric BMWs to study use of EVs to support power grids
- Italy’s ASPI announces plans to install cross-country ultra-fast EV charging network
- EV ownership costs significantly lower than conventional models: French Study